GlaxoSmithKline plc (ADR)  

(Public, NYSE:GSK)   Watch this stock  
Find more results for GSK
48.26
+0.13 (0.27%)
Pre-market: 48.49 +0.23 (0.48%)
Aug 27, 4:00AM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 48.10 - 48.40
52 week 46.01 - 56.73
Open 48.13
Vol / Avg. 100.00/4.50M
Mkt cap 114.87B
P/E 14.97
Div/yield 0.65/5.50
EPS 3.22
Shares 4.86B
Beta 0.59
Inst. own 6%
Oct 22, 2014
Q3 2014 GlaxoSmithKline PLC Earnings Release - 7:00AM EDT - Add to calendar
Sep 9, 2014
GlaxoSmithKline PLC Investor and Analyst Event at the European Respiratory Society - 7:30AM EDT - Add to calendar
Jul 23, 2014
Q2 2014 GlaxoSmithKline PLC Earnings Call
Jul 23, 2014
Q2 2014 GlaxoSmithKline PLC Earnings Release
Jul 15, 2014
Codexis Inc Announces Technology Collaboration and License Agreement With GSK Conference Call - Webcast
Jun 2, 2014
GlaxoSmithKline at Jefferies Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 12.62% 21.23%
Operating margin 20.45% 27.58%
EBITD margin - 34.46%
Return on average assets 7.17% 13.47%
Return on average equity 41.20% 84.96%
Employees 99,817 -
CDP Score - 98 A

Address

980 Great West Road
BRENTFORD, ENG TW8 9GS
United Kingdom - Map
+44-20-80475000 (Phone)
+44-20-80477807 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK�s principal pharmaceutical products include medicines in therapeutic areas: respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines and human immunodeficiency virus (HIV). The Company operates in three primary areas of business: Pharmaceuticals, Vaccines and Consumer Healthcare. On January 30, 2013, GSK acquired additional 29.3% interest in GlaxoSmithKline Consumer Healthcare Ltd. In May 2013, GlaxoSmithKline PLC acquired Okairos AG. In December 2013, Suntory Beverage & Food Ltd fully acquired Lucozade Ribena Suntory Limited from GlaxoSmithKline plc.

Officers and directors

Andrew Philip Witty Chief Executive Officer, Executive Director
Age: 49
Bio & Compensation  - Reuters
Simon Dingemans Chief Financial Officer, Executive Director
Age: 50
Bio & Compensation  - Reuters
Moncef Slaoui Chairman - Global Research & Development and Vaccines, Executive Director
Age: 54
Bio & Compensation  - Reuters
Deirdre P. Connelly President - North American Pharmaceuticals
Age: 53
Bio & Compensation  - Reuters
Roger Connor President - Global Manufacturing & Supply
Bio & Compensation  - Reuters
Shah Abbas Hussain President - Europe, Japan & EMAP
Age: 47
Bio & Compensation  - Reuters
Patrick Vallance President - Pharmaceuticals R&D
Bio & Compensation  - Reuters
Emma Walmsley President - Consumer Healthcare Worldwide
Bio & Compensation  - Reuters
Daniel Troy Senior Vice President, General Counsel
Bio & Compensation  - Reuters
Claire Thomas Senior Vice President - Human Resources
Bio & Compensation  - Reuters